1. Home
  2. EM vs MOLN Comparison

EM vs MOLN Comparison

Compare EM & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smart Share Global Limited

EM

Smart Share Global Limited

HOLD

Current Price

$1.14

Market Cap

289.1M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.36

Market Cap

158.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EM
MOLN
Founded
2017
2004
Country
China
Switzerland
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
289.1M
158.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EM
MOLN
Price
$1.14
$4.36
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$1.25
$8.38
AVG Volume (30 Days)
45.5K
3.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.30
N/A
Revenue Next Year
$5.26
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$3.36
52 Week High
$1.46
$5.36

Technical Indicators

Market Signals
Indicator
EM
MOLN
Relative Strength Index (RSI) 47.73 39.42
Support Level $1.13 $3.51
Resistance Level $1.18 $4.63
Average True Range (ATR) 0.02 0.26
MACD 0.00 -0.10
Stochastic Oscillator 50.00 19.05

Price Performance

Historical Comparison
EM
MOLN

About EM Smart Share Global Limited

Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: